Rodman & Renshaw initiated coverage on Cormedix with a new price target
$CRMD
Biotechnology: Pharmaceutical Preparations
Health Care
Rodman & Renshaw initiated coverage of Cormedix with a rating of Buy and set a new price target of $13.00
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/7/2025 | $18.00 | Outperform | Leerink Partners |
1/13/2025 | $15.00 | Buy | D. Boral Capital |
8/26/2024 | $13.00 | Buy | Rodman & Renshaw |
8/10/2023 | $6.00 | Outperform | RBC Capital Mkts |
Leerink Partners initiated coverage of Cormedix with a rating of Outperform and set a new price target of $18.00
D. Boral Capital initiated coverage of Cormedix with a rating of Buy and set a new price target of $15.00
Rodman & Renshaw initiated coverage of Cormedix with a rating of Buy and set a new price target of $13.00